Dimensional Fund Advisors LP Boosts Stake in Cryoport, Inc. (NASDAQ:CYRX)

Dimensional Fund Advisors LP lifted its stake in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 8.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 850,216 shares of the company's stock after acquiring an additional 63,301 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.72% of Cryoport worth $6,615,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Franklin Resources Inc. raised its position in shares of Cryoport by 0.4% in the 4th quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock worth $3,012,000 after acquiring an additional 1,512 shares in the last quarter. Rhumbline Advisers grew its stake in Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock worth $492,000 after purchasing an additional 1,764 shares during the period. Penbrook Management LLC increased its holdings in Cryoport by 6.0% in the fourth quarter. Penbrook Management LLC now owns 52,570 shares of the company's stock worth $409,000 after purchasing an additional 2,975 shares in the last quarter. Invesco Ltd. lifted its stake in Cryoport by 11.6% in the fourth quarter. Invesco Ltd. now owns 51,803 shares of the company's stock valued at $403,000 after buying an additional 5,364 shares during the period. Finally, American Century Companies Inc. lifted its stake in Cryoport by 12.0% in the fourth quarter. American Century Companies Inc. now owns 51,443 shares of the company's stock valued at $400,000 after buying an additional 5,508 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on CYRX shares. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Cryoport in a research note on Thursday, May 8th. Morgan Stanley reduced their price target on shares of Cryoport from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. UBS Group upped their price objective on shares of Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Guggenheim reissued a "buy" rating and set a $10.00 price objective on shares of Cryoport in a research report on Wednesday, April 16th. Finally, Roth Mkm reaffirmed a "buy" rating and issued a $15.00 target price on shares of Cryoport in a research report on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $11.00.

Insider Transactions at Cryoport

In related news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares of the company's stock, valued at $4,814,359.71. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 19,830 shares of company stock valued at $118,353 over the last ninety days. 10.00% of the stock is currently owned by insiders.

Cryoport Stock Up 1.6%

CYRX traded up $0.11 during trading on Friday, hitting $6.84. 131,678 shares of the company's stock were exchanged, compared to its average volume of 541,237. Cryoport, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $14.20. The stock has a market cap of $342.94 million, a P/E ratio of -2.02 and a beta of 1.92. The business's 50 day moving average is $5.95 and its two-hundred day moving average is $6.86. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. As a group, equities analysts expect that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.